PARIS (Reuters) – A French court on Wednesday ruled that the families of victims of Depakine, an epilepsy drug that caused birth malfunctions and slow neurological development when taken during pregnancy, could join a class action lawsuit against healthcare group Sanofi, France Info radio reported, quoting news agency AFP.
Victims association APESAC, that represents 7,500 families, had launched the class action in September 2021 against Sanofi, which was also placed under formal investigation on charges of manslaughter over Depakine in 2020.
Source: Read Full Article
